Comparative Pharmacology
Head-to-head clinical analysis: HYDROXYCHLOROQUINE versus QUININE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROXYCHLOROQUINE versus QUININE SULFATE.
Hydroxychloroquine vs QUININE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxychloroquine is a 4-aminoquinoline antimalarial agent that accumulates in lysosomes and inhibits Toll-like receptor signaling, reduces cytokine production, and interferes with antigen presentation. It also inhibits heme polymerase in malarial parasites, leading to toxic heme accumulation.
Quinine sulfate is a blood schizonticide effective against the asexual erythrocytic forms of Plasmodium spp. It interferes with the parasite's ability to digest hemoglobin, leading to accumulation of toxic heme and parasite death. Quinine also has mild analgesic and antipyretic effects, and may depress cardiac conduction and contractility.
400 mg orally once daily or 200 mg orally twice daily, then 200-400 mg orally once daily for maintenance, depending on indication.
324 mg orally every 8 hours for 7 days (for treatment of chloroquine-resistant falciparum malaria, in combination with other antimalarials).
None Documented
None Documented
Clinical Note
moderateHydroxychloroquine + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Hydroxychloroquine."
Clinical Note
moderateHydroxychloroquine + Artemether
"The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Artemether."
Clinical Note
moderateHydroxychloroquine + Chloroquine
"The serum concentration of Chloroquine can be decreased when it is combined with Hydroxychloroquine."
Clinical Note
moderateTerminal half-life: 30-60 days (prolonged due to extensive tissue binding); clinical context: requires loading dose for rapid effect.
Terminal elimination half-life: 18 hours (range 16-21 hours) in healthy adults; prolonged in renal impairment (up to 25-30 hours) and severe hepatic impairment.
Primarily renal (30-60% unchanged); minor hepatic metabolism; fecal elimination accounts for ~20-30%.
Renal: 20% unchanged; hepatic metabolism (CYP3A4, CYP2C9) accounts for 80% with metabolites (primarily 3-hydroxyquinine) excreted renally and fecally. Biliary excretion is minor (<5%).
Category A/B
Category D/X
Antimalarial / DMARD
Antimalarial
Hydroxychloroquine + Lumefantrine
"The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Lumefantrine."